An immunoassay for type I collagen α1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis

Bone

Volumn 32, Issue 1, 2003, Pages 20-26

  Garnero, P ^a   Delmas, P D ^b  

^a Synarc Lyon   (France)

^b NONE

Author keywords

Bisphosphonate; Bone resorption; Estrogens; Osteoporosis; Type I collagen

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; ESTRADIOL; TYPE 1 COLLAGEN ALPHA1 HELICOIDAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN THERAPY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NORMAL HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH;

EID: 0037262583     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00922-5     Document Type: Article

References (22)

1. Bonde M., Qvist P., Fledelius C., Riss B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 40:1994;2022-2025.
2. Cooper C., Stakkesdad J.S., Radwicki S., et al. Matrix delivery transdermal 17 β estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int. 9:1999;358-366.
3. Delmas P.D., Pornel B., Felsenberg D., et al. A dose ranging trial of a matrix trasndermal 17 b estrdaiol for the prevention of bone loss in early postmenopausal women. Bone. 24:1999;517-523.
4. Delmas P.D., Gineyts E., Bertholin A., Garnero P., Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res. 8:1993;643-648.
5. Delmas P.D., Confavreux E., Genolet G., Garnero P., Gibelin B., Folens C., Yates J. Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women. Osteoporos Int. 11:(Suppl 2):2000;S208.
6. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 11:(Suppl 6):2000;S2-17.
7. Delmas P.D. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 11:(Suppl 6):2000;S66-76.
8. Eyre D.R., Knoob T.J., Van Ness K.P. Quantitation of hydroxypyridnium cross-links in collagen by high performance liquid chromatography. Ann Biochem. 137:1984;380-388.
9. Fugimoto D., Suzuki M., Uchiyama A., Miyamoto S., Inoue T. Analysis of pyridinoline, a cross-linking compound of collagen fibers, in urine. J Biochem. 137:1984;380-388.
10. Garnero P., Borel O., Byrjalsen I., Ferraras M., Drake F., Foged N.T., Delmas P.D., Delaissé J.M. The collagenolytic activity of cathepsin K is unique amongst mammalian proteinases. J Biol Chem. 273:1998;32347-32352.
11. Garnero P., Delmas P.D. Laboratory assessment of postmenopausal osteoporosis. Seibel M.J., Robins S.P., Bilezikian J.P. Dynamics of bone and cartilage metabolism principles and clinical applications. 1998;465-477 Academic Press, San Diego CA.
12. Garnero P., Delmas P.D. Measurements of biochemical markers methods and limitations. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of bone biology. 1996;1277-1291 Academic Press, San Diego, CA.
13. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone crosslinks excretion. J Bone Miner Res. 10:1995;641-649.
14. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 11:1996;827-834.
15. Gluer C.C., Blake G., Lu Y., Blunt B.A., Jergas M., Genant H.K. Accurate assessment of precision errors how to measure the reproducibility of bone densitomerty techniques. Osteoporos Int. 5:1995;262-270.
16. Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int. 11:(Suppl 6):2000;S30-S44.
17. Hanson D.A., Weiss M.A.E., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1992;1251-1258.
18. Ju J., Leigh S., Byrne M., van der Rest M., Liu V., Krane S. A new marker for measuring bone resorption development of an ELISA for a 14 amino acid peptide (residues 620-633) derived from α1 (I) chain. J Bone Miner Res. 12:(Suppl 1):1997;S178.
19. Karsdal K., Garnero P., Ferreras M., Risteli J., Foged N.T., Delaissé J.M. The type 1 collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 16:(Suppl 1):2001;S195.
20. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 9:1994;1643-1649.
21. Sassi M.-L., Eriksen H., Ristelli L., Niemi S., Mansell J., Gowen M., Ristelli J. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen Loss of antigenicity by treatment with cathepsin K. Bone. 26:2000;367-373.
22. Seyedin S., Zuk R., Kung V., Daniloff Y., Shepard K. An immunoassay to urinary pyridinoline the new marker of bone resorption. J Bone Miner Res. 8:1993;635-642.